03:50 PM EDT, 09/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Shares of Pfizer ( PFE ) are up more than 5% D/D after the announced agreement today with the U.S. government to lower drug prices in the U.S. This is the first agreement that the U.S. government made with a pharmaceutical firm, in which Pfizer's ( PFE ) medicines will be available in the U.S. at an average discount rate of 50% via the direct purchasing platform, TrumpRx.gov. Under this agreement, Pfizer ( PFE ) will get a three-year grace period from pharmaceutical tariffs while it continues to invest in its manufacturing in the U.S. We find the news positive for Pfizer ( PFE ) and expect other agreements with other major pharmaceuticals to follow suit. We raise our target price to $30 from $28, 9.3x our 2026 EPS estimate, a discount to PFE's historical forward P/E average. We keep our 2025 EPS estimate at $3.07 and raise our 2026 EPS view to $3.21 from $3.06.